AOD-9604 Prescription: How to Get One

What “getting a prescription” would actually mean for AOD-9604

When people search for an “AOD-9604 prescription,” they usually picture the same process that gets them any other medication: see a provider, get a script, take it to a pharmacy, walk out with a labeled product. For AOD-9604 in 2026, that picture does not hold — and the reason is more interesting than a simple “it’s banned.”

In the US, a peptide can reach a patient legally through one of three doors. The first is FDA approval: a finished, approved drug a licensed prescriber writes for and a normal pharmacy dispenses (this is how semaglutide and tirzepatide work). The second is compounding: a substance that isn’t an approved drug but is allowed to be made up by a licensed 503A pharmacy for a specific patient with a prescription. The third is the research-only market, where vials are sold “for laboratory use, not for human consumption” — which is not a patient route at all, however it’s marketed.

AOD-9604 fails the first door and, as of mid-2026, is shut out of the second. That makes it genuinely different from most of the compounds covered elsewhere on this site, and it’s why this page spends less time on intake logistics and more on the question people actually need answered: why isn’t there a clean prescription, and what does that mean?

Why AOD-9604 was never approved — the part most pages skip

AOD-9604 is not an obscure research peptide that nobody ever bothered to test. It is the opposite. It was deliberately built as a prescription weight-loss drug and put through real human trials — and it is one of the very few peptides in this whole conversation where we can say, with published evidence, that the headline use was tested and did not pan out.

The molecule is a stabilized fragment of human growth hormone, derived from work at Monash University in the early 1990s that tried to isolate growth hormone’s fat-burning activity from its blood-sugar effects. An Australian company, Metabolic Pharmaceuticals, licensed that work and developed AOD-9604 as an oral anti-obesity candidate. Early studies looked promising: a roughly 12-week trial reported about 2.6 kg of weight loss on the peptide versus around 0.8 kg on placebo — modest, but enough to justify a larger study.

That larger study is the one that matters. A 24-week Phase 2b trial enrolled 536 obese adults across multiple low oral doses, double-blind and placebo-controlled — the proper test. It did not meet its primary weight-loss endpoint; the difference from placebo was not statistically significant at the doses studied. Notably, the safety side looked clean (no IGF-1 elevation, no glucose problems), but the efficacy simply wasn’t there at a magnitude that could support an obesity drug. Metabolic Pharmaceuticals discontinued development for obesity in 2007 and never advanced it to Phase 3.

Note: The trials that “failed” used AOD-9604 as an oral tablet, the form Metabolic was developing. The injectable vials sold today as “research peptides” are a different product entirely — not the formulation that was studied, and of unknown content. The disappointing trial result and the gray-market injectable are two separate things, and neither one supports self-use.

This history is the quiet engine behind everything else on this page. There is no AOD-9604 brand to prescribe because the company that tried to make one couldn’t show it worked. That same thin efficacy record is what the FDA later leaned on when it decided the compound didn’t belong on the list of substances pharmacies are allowed to compound.

Where AOD-9604 sits in the 2026 compounding picture

The peptide-compounding landscape moved a lot in 2024 and again in 2026, so it’s worth being precise about where AOD-9604 actually lands — because it is not in the group of peptides whose access is opening up.

In late 2023 the FDA placed a long list of peptides, AOD-9604 among them, into “Category 2” of its interim 503A bulks list — effectively a “do not compound” designation while the agency studied safety concerns. A group of compounding interests sued over how that was done, and the dispute specifically named four peptides: AOD-9604, CJC-1295, ipamorelin, and thymosin alpha-1. In September 2024, the nominations for those substances were withdrawn and they were taken out of Category 2.

Here’s the trap many summaries fall into: being removed from Category 2 is not the same as being approved or made compoundable. Removal just took the substance out of the “prohibited pending review” bucket and sent it to the FDA’s Pharmacy Compounding Advisory Committee (PCAC) for a formal up-or-down look. For a peptide to be lawfully compounded, it has to make it onto the Category 1 bulks list — and AOD-9604 didn’t. At the PCAC meetings in October and December 2024, the committee reviewed AOD-9604 (both the free-base and acetate forms) and voted against including it on the 503A bulks list, in line with the FDA’s own recommendation. The committee’s stated concerns were the familiar ones: insufficient human safety data and a lack of reproducible efficacy — exactly the shadow cast by that failed Phase 2b trial.

That leaves AOD-9604 in an awkward spot for 2026. It is no longer formally “Category 2,” but it is also not on the Category 1 list, so it remains not lawfully compoundable. And unlike peptides such as BPC-157, TB-500, or MOTS-C — which were removed from Category 2 in April 2026 and scheduled for a fresh PCAC review on July 23–24, 2026 — AOD-9604 is not on that July docket, nor on the separate review slated before February 2027. It has already had its hearing and lost. So while the broader regulatory story is genuinely in motion, AOD-9604’s particular door is, for now, the one swinging shut rather than open.

This status is current as of June 2026 and could change; the FDA can revisit substances, and advocacy in this space is active. But anyone telling you today that AOD-9604 is “back” or “newly legal to compound” is either confusing it with the July-2026 cohort or not reading the votes that already happened.

Who could write the prescription — and why a pharmacy can’t fill it

Suppose you ask a provider about AOD-9604 anyway. There’s no special “controlled substance” barrier on the prescriber side — it’s not a scheduled drug, so in principle a wide range of licensed clinicians (physicians, and in many states nurse practitioners or physician assistants) could put the word on a prescription pad.

The wall is downstream, at the pharmacy. A 503A compounding pharmacy can only legally compound from a bulk substance that is a component of an FDA-approved drug, has an applicable USP or NF monograph, or appears on the Category 1 bulks list. AOD-9604 meets none of those: there’s no approved AOD-9604 drug, no monograph, and (as above) it was voted off the bulks-list path. So a compliant pharmacy has no lawful basis to fill the script — and most won’t, because doing so exposes them to FDA enforcement.

That’s the practical reality behind the search term. A prescription is only useful if something legitimate can be done with it. For an approved weight-loss medication, the script is fillable the same day. For AOD-9604, the script — even if written — currently dead-ends at the pharmacy counter. This is the same compounding gap that affects several wellness peptides, covered in more depth in our 503A vs 503B explainer and the reclassification deep-dive. What makes AOD-9604 distinct is that its gap isn’t a temporary “pending review” pause — it’s a “reviewed and declined” outcome.

What an honest provider conversation looks like

None of this means you can’t talk to a clinician about AOD-9604. A legitimate evaluation for any metabolic or weight concern starts the same way: history, goals, relevant labs, and a realistic discussion of what the evidence supports. A provider who knows this compound well is likely to tell you the same thing the trials did — that the human data for AOD-9604 as a fat-loss agent is weak, and that approved options have far stronger Phase 3 evidence behind them.

The genuine warning sign is the inverse: any “clinic” or website that will issue an AOD-9604 “prescription” with no real evaluation, no labs, and no follow-up, and conveniently ship you a vial. That pattern is not legitimate prescribing; it’s a sales funnel wearing a lab coat, and the product on the other end is the unregulated research-grade material discussed below. For how to separate real providers from that, see how to choose a peptide clinic and the broader prescriber landscape guide. The route-by-route comparison of what people actually do — telehealth, in-person clinics, and the limits of each — lives on our how to get AOD-9604 page.

Anti-doping status and the research-chemical trap

Two cautions are worth stating plainly. First, AOD-9604 is prohibited in sport. The World Anti-Doping Agency lists it, alongside the related hGH fragment 176-191, by name under its growth-hormone-fragments category — prohibited at all times, in and out of competition. Any tested athlete should treat it as banned; its lack of approval anywhere in the world is part of why WADA classifies it the way it does.

Second, the research-only market is not a workaround. Because there’s no legal compounding route, the AOD-9604 sold online is almost entirely “for research use only” material. That labeling isn’t a technicality — it means the vial was never made, tested, or released as a medicine. Content and purity vary between sellers and between batches, and a “standard internet dose” applied to a product of unknown concentration is still unsafe, no matter how confident the protocol on a forum sounds. The combination of a discontinued, never-approved compound and an unverified gray-market supply is exactly the situation US compounding rules exist to prevent. We cover that market’s realities, without sourcing instructions, in research peptides explained.

The bottom line

AOD-9604 occupies an unusual place: it’s not a peptide that simply hasn’t been studied, and it’s not one caught in a temporary regulatory pause. It’s a compound that was built to be a prescription weight-loss drug, was properly tested, fell short, and has since been formally declined for compounding. So the honest answer to “how do I get an AOD-9604 prescription?” in 2026 is that, through legitimate channels, you largely can’t — and the same evidence gap that closed the regulatory door is a reason to think hard about whether it’s worth chasing through any other one. If weight loss is the goal, the approved GLP-1 medications have the human evidence and the lawful, fillable prescription route that AOD-9604 lacks.